Anti-Estrogen Receptor beta 2 Antibody [57/3] (A279408)

Anti-Estrogen Receptor beta 2 Antibody [57/3]

Mouse monoclonal [57/3] antibody to Estrogen Receptor beta 2.

This antibody recognises the estrogen receptor beta 2 isoform, expressed in cell nuclei of a range of human tissues including the ovary, placenta, testis and vas deferens. No cross-reactivity is seen with estrogen receptor beta 1 isoform. The detection of estrogen (ER) and progesterone (PR) receptors using immunohistochemical staining of formal fixed paraffin embedded (FFPE) tissue, has gradually replaced ligand binding assays (LBA), to become the most common method for the determination of the ER/PR status of breast tumors. Approximately 75% to 80% of breast tumors have estrogen and/or progesterone receptors, and the presence of these receptors helps determine both the patient’s prognosis and the effectiveness of hormonal therapy

IHC-P 1: 1:50 - 1:500

Human

Synthetic peptide sequence CGMKMETLLPEATMEQ from the C terminus of the human estrogen receptor beta 2 isomer.

CGMKMETLLPEATMEQ

Mouse

Monoclonal

57/3

1 mg/ml

Liquid

Supplied in Phosphate Buffered Saline with <0.1% Sodium Azide.

Shipped at ambient temperature. Upon delivery aliquot and store at -20°C. When thawed, aliquot the sample as needed. Short term (up to 4 weeks): store at 4°C. Long term: store at -20°C. Avoid freeze / thaw cycles. Storage in frost free freezers is not recommended.

Mouse anti Human Estrogen Receptor beta 2 antibody, clone 57/3 recognizes the estrogen receptor beta 2 isoform, expressed in cell nuclei of a range of human tissues including the ovary, placenta, testis and vas deferens. No cross-reactivity is seen with estrogen receptor beta 1 isoform. The detection of estrogen (ER) and progesterone (PR) receptors using immunohistochemical staining of formal fixed paraffin embedded (FFPE) tissue, has gradually replaced ligand binding assays (LBA), to become the most common method for the determination of the ER/PR status of breast tumors. Approximately 75% to 80% of breast tumors have estrogen and/or progesterone receptors, and the presence of these receptors helps determine both the patient’s prognosis and the effectiveness of hormonal therapy